Nanoparticles could have giant impact on drug development

05/7/2013 | Reuters

Bind Therapeutics has agreed to three deals potentially worth a total of $1 billion to help drugmakers develop nanomedicine. Drugs incorporating nanoparticles of polymers, gold and graphene are in various stages of development, including 117 oncology drugs, according to Thomson Reuters Pharma. Nanoparticles may allow targeted treatment of tumors with fewer side effects than conventional therapies and may also be useful in drugs for inflammatory disorders, pain, and heart and brain diseases, as well as diagnostics.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ